Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19

Area of Science:

• Cardiovascular Medicine
• Infectious Diseases
• Clinical Biochemistry

Background:

• Lipoprotein(a) (Lp(a)) is implicated in thrombosis and inflammation.
• Its role in severe COVID-19 pathogenesis and prognosis is debated.
• Understanding Lp(a)'s impact on COVID-19 outcomes is crucial for patient management.

Purpose of the Study:

• To investigate the association between Lp(a) and thrombo-inflammation biomarkers in COVID-19 patients.
• To determine if Lp(a) predicts thrombotic events or adverse clinical outcomes in hospitalized COVID-19 patients.

Main Methods:

• A cohort of 564 hospitalized COVID-19 patients was enrolled.
• Lipoprotein(a) (Lp(a)) levels were measured at admission.
• Biomarkers for prothrombotic (D-dimer) and proinflammatory (CRP, procalcitonin, WBC) states were assessed.
• Thrombotic events and composite clinical endpoints (ICU admission/death) were recorded.

Main Results:

• Median Lp(a) was 13 mg/dL; 11% experienced thrombotic events, 15% met the composite endpoint.
• Lp(a) showed no significant association with D-dimer, CRP, procalcitonin, or WBC levels.
• Multivariable analyses revealed no link between Lp(a) and the risk of thrombotic events or adverse clinical outcomes.

Conclusions:

• Lipoprotein(a) does not appear to influence key biomarkers of thrombotic activity or systemic inflammation in COVID-19.
• Lp(a) levels at admission do not predict thrombotic events or adverse clinical outcomes in hospitalized COVID-19 patients.
• These findings suggest Lp(a) has a limited prognostic role in the clinical course of COVID-19.